Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2018-04-13
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of giving bortezomib and romidepsin
together in treating patients with chronic lymphocytic leukemia (CLL), small lymphocytic
lymphoma (SLL), indolent B-cell lymphoma, peripheral T-cell lymphoma (PTCL) or cutaneous
T-cell lymphoma (CTCL). Bortezomib and romidepsin may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth.